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Resumo 
A terapêutica da leucemia linfoblástica aguda (LLA) em idade pediátrica é um exemplo de sucesso em 
oncologia e está associada a altas taxas de cura. Porém, há ainda muitas crianças e adultos que 
recidivam ou que apresentam doença primariamente refratária, sendo que a maioria tem doença 
considerada resistente. A aplicação de “regimes pediátricos” de quimioterapia a adultos que tolerem, 
leva à obtenção de melhores resultados nesta população. Além do transplante alogénico de células 
estaminais hematopoiéticas, a investigação de novas terapêuticas para a LLA dirigidas a alvos 
moleculares específicos é considerável e novos fármacos surgem. Destacam-se: a utilização de 
inibidores tirosina cinase na LLA Philadelphia+ bem como o seu potencial num subtipo recentemente 
identificado da doença – LLA Philadelphia-like; e a imunoterapia que se afirma também neste 
contexto através da utilização de anticorpos monoclonais como o blinatomumab (recentemente 
aprovado pela EMA e FDA) bem como a infusão de células T geneticamente modificadas – CAR T 
cells.  O melhor conhecimento da biologia da LLA de fenótipo T, para a qual as terapêuticas 
supramencionadas não se revelam muito promissoras, é essencial - há avanços, apesar de 
desproporcionais. Novas opções terapêuticas que atualmente são utilizadas apenas na terapêutica de 
resgate poderão ser implementadas nos regimes iniciais num curto prazo.  
 
Abstract 
 
Therapy for acute lymphoblastic leukemia (ALL) in pediatric age is an example of 
success in oncology and is associated with high cure rates. However, there are still 
many children and adults who relapse or have primarily refractory disease, most of 
them have resistant disease. The application of “pediatric inspired” chemotherapy 
regimens to adults who tolerate, improve outcomes in this population. Beyond 
allogenic hematopoietic stem cell transplantation, investigation of new therapies for 
ALL directed at specific molecular targets is considerable and new pharmacologic 
agents are arising. These include: the use of tyrosine kinase inhibitors in Philadelphia 
chromosome positive ALL as well as its potential use in a recently identified subtype 
of the disease – Philadelphia-like ALL; and immunotherapy that appears in this 
context through the use of monoclonal antibodies, such as blinatumomab (recently 
approved by EMA and FDA), as well as the infusion of genetically modified T cells – 
CAR T cells. A better knowledge of T phenotype ALL biology, for which the 
aforementioned therapies do not reveal as promising, is essential – there is progress 
although disproportionate. New therapeutic options that, at present, are used only as 
rescue therapy may be implemented in frontline regimens in a near future.
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1. Introduction 
 
1.1. Perspective of ALL with standard therapy and its outcomes 
 
ALL is among the few oncologic diseases that do not spare age groups. 60% of cases 
are diagnosed in patients under the age of 20 and 11% in patients older than 65 (1,2). 
This makes the approach to ALL a complex one, once patient and leukemic factors 
must be considered when planning therapy (1). 
 
Chemotherapy regimens for the treatment of pediatric ALL are considered an 
example of success in oncologic therapy(1,3). The optimization of therapeutic regimens 
provided cure rates as high as 90% for patients who once had a dismal prognosis (1,4,5). 
The improvements in survival are due primarily to the decrease in relapse rates, with 
weak improvements during the last 20 years for the children who still relapse. 
 
For the adults the same success was not found using similar approaches. These 
regimens result in complete remission (CR) rates for about 80 to 90% but only 40 to 
50% for cure (1,6,7). The addition of agents directed at specific targets improved 
survival and the cure rates in adults (1,7,8). 
 
Relapsed ALL continues particularly challenging in all age groups making it one of 
the main causes of cancer related death in children worldwide and having an even 
worse prognosis in adults. 
 
The majority of children who relapse is going to reach a second complete remission 
(CR2) in contrast to the adult population that in the best scenario do it in less than 
50% of cases. Even when a second complete remission is obtained, the response is not 
sustainable in most cases. For each subsequent relapse, achieving a new remission 
becomes increasingly difficult and the survival becomes extraordinarily low. 
 
Refractory ALL is also challenging with a survival rate close to 30%. For those who 
do not achieve a remission the options are limited. 
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1.2. New horizons for ALL therapy 
 
The purpose of this review is to integrate the major advances concerned with ALL 
therapy that are being reported in the literature. Subjects related to standard 
chemotherapy regimens; bone marrow transplantation and general support to the 
oncologic patient will not be discussed in detail here. 
 
In the present review subjects will be presented as follows: 
- A major modification in standard chemotherapy regimens – the application of 
pediatric “inspired” regimens to the adult population.  
- Targeted therapies to Philadelphia Chromossome + ALL and the potential to 
adopt a similar strategy in a recently described entity of the disease – 
Philadelphia like ALL (Ph-like ALL). 
- Immunotherapy as a treatment for ALL - Probably the most highlighted 
subject in virtue of its recent promising results with different monoclonal 
antibodies and the use of CAR T cells.  
- T phenotype ALL will be discussed afterwards once the most powerful 
directed therapies being developed at present are not used to treat this subtype 
of the disease however progress is also being made. 
2. Application of pediatric intensive chemotherapy regimens for adolescents 
and young adults (AYA) with ALL 
 
There is not a universally accepted definition of age subgroups in ALL however it can 
be considered that classic pediatric ALL patients range from 0 to 14 years, 
adolescents from 15 to 19, young adults from 20 to 39, adults from 40 to 60 and older 
adults and elderly patients include those beyond the age of 65. 
 
Several biologic factors are present in less young patients that confer them a poorer 
prognostic, such as differences in cytogenetics, molecular genetics, 
immunophenotype and response and tolerability to intensive chemotherapy regimens.  
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Regimens applied to adults typically consist in the use of intensive mielossupressive 
agents including daunorubicin, cytarabine, cyclophosphamide as well as allogenic 
hematopoietic stem cell transplant when complete remission is achieved (16,17,18).  
 
By contrast, pediatric regimens focus on the Berlin-Frankfurt-Munster (BFM) ALL 
therapy framework or on the Dana Farber Cancer Institute (DFCI) ALL consortium 
protocols: glucocorticoids, vincristine, asparaginase, CNS prophylaxis and prolonged 
maintenance therapy. Asparaginase related toxicity is one of the major problems 
when pediatric regimens are applied to adults (9,13,19,20). 
 
The success achieved in the treatment of pediatric ALL did not apply to adults (9,10). In 
the last decades, the treatment of adults with ALL resulted in survival rates of around 
40% (11,12). However, multiple studies have demonstrated that AYA treated with 
pediatric regimens of intensive chemotherapy achieve better responses than when 
treated with standard adult intensive chemotherapy regimens. 
 
This was first demonstrated in a retrospective comparative study with 321 AYA that 
were treated in various clinical trials either by the Children’s Cancer Group (CCG) or 
by the Cancer and Leukaemia Group B (CALBG) from 1988 to 2001 (13). 
 
CR rates among pediatric and adult cohorts were the same, however AYA patients 
treated by the CCG achieved a global survival at 7 years of 67% in contrast to a 
global survival of 47% achieved by AYA patients treated by the CALGB. 
 
Similar studies in other countries have shown similar outcomes (14,15). 
 
Based on these retrospective comparisons, several prospective studies using “pediatric 
inspired” and “unmodified pediatric protocols” in AYA patients in different countries 
have shown favourable outcomes with uniformity. These studies included both 
standard and high risk ALL patients. The biggest prospective study in this subject is 
the ongoing US intergroup study, C10403, and aims to demonstrate that adult cancer 
cooperative groups can deliver a “true pediatric’’ regimen to AYA patients achieving 
similar outcomes. 
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Explaining the differences in outcome between pediatric and adult protocols are 
several factors: 
- Differences in protocol design and treatment intensity, with pediatric protocols 
including more nonmielossupressive agents with activity on lymphoblasts: 
asparaginase, vincristine and glucocorticoids. 
- Central nervous system (CNS) prophylaxis is administered earlier, with 
greater frequency and for more prolonged periods in pediatric trials. 
- Possibly, a more accurate administration of therapy in pediatric institutions 
and a better compliance of adolescent patients treated in a pediatric facility. 
 
The age limit for the administration of pediatric intensive regimens is not well 
defined. Some studies used these regimens in patients up to 50 to 60 years old. 
Therapy related mortality and toxicity increase in older patients (14). Differences in the 
metabolism of chemotherapeutic agents, depleted marrow reserve and greater 
extramedullary toxicity increase the frequency of life threatening infections, organ 
failure, treatment delays and dose reductions in planned therapy in these patients. 
 
Based on these studies, current recommendations suggest treating AYA patients with 
pediatric regimens since diagnosis with the purpose of achieving remission and 
potential cure (21). 
3. Philadelphia chromosome positive (Ph+) ALL and Philadelphia 
chromosome-like (Ph-like) ALL – the role of tyrosine kinase inhibitors 
 
3.1. Philadelphia Chromossome positive (Ph+) ALL 
 
Philadelphia chromosome arises from a translocation of the ABL gene on 
chromosome 9 to the BCR gene on chromosome 22 giving rise to a chimeric BCR-
ABL fusion gene. A Bcr-Abl protein results, being a constitutively active tyrosine 
kinase, central to the pathogenesis of ALL. A tyrosine kinase is an enzyme 
responsible for the activation of proteins in signal transduction cascades by 
phosphorylation. This aberrant Bcr-Abl tyrosine kinase leads to leukemogenesis 
altering signalling pathways that lead to increased cell proliferation, survival and self-
renewal. 
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Philadelphia chromosome is present in approximately 20 to 30% of adults with ALL 
but in only 2 to 3% of children (22,23). It is the most common chromosomal 
abnormality in adult ALL population. 
 
Recently, greater interest has arisen in the underlying biology of this specific 
leukemia associated with the fact that more mature information about its treatment 
has been accumulated (24). 
 
The bad prognosis of this relatively rare leukemia has led to the adoption of 
therapeutic strategies like the allogenic hematopoietic stem cell transplant (aHSCT) 
and tyrosine kinase inhibitors (TKIs), despite the scarcity of randomized clinical trials 
(24). In adults aHSCT in first remission remains the only proven curative strategy for 
transplant eligible patients. The introduction of TKIs has improved the depth and 
duration of CR allowing more patients to proceed to transplant.  
 
The first Bcr-Abl TKI was imatinib and it was approved for the treatment of chronic 
myeloid leukemia (CML) showing high efficacy; subsequently, second generation 
TKIs were developed with the purpose of overcoming resistance and intolerance to 
imatinib. Dasatinib, nilotinib, bosutinib and ponatinib are currently available second-
generation Bcr-Abl TKIs. 
 
Early detection of t(9,22) is now a vital component of the approach to ALL. Bone 
marrow samples should be sent for cytogenetic and molecular study accompanied by 
a specific request for detection of Philadelphia chromosome/ BCR-ABL (24). 
 
In the past, chemotherapy applied to Ph+ ALL was identical to that applied to Ph- 
ALL, however patients with Ph + ALL achieved complete remissions less frequently, 
with CR rates of 60 to 85% (25), and relatively short durations of remission of about 9 
months. It was assumed then, that chemotherapy applied to these patients should 
consist in the most intensive regimens available.  
 
 7 
 
Once the outcomes with standard chemotherapy were discouraging, TKIs were 
adopted globally in Ph+ ALL treatment protocols after showing promising outcomes 
in initial studies that demonstrated activity in relapsed disease (26,27). 
 
Imatinib is the most used and most extensively studied tyrosine kinase inhibitor in the 
context of ALL. It has been combined with chemotherapy in different schedules and 
timings however there has never been a randomized controlled trial so its benefits are 
evaluated by reference to historic control patients (24). Several retrospective and 
prospective studies of the use of imatinib in Ph+ ALL are now published and they all 
have as a prominent finding a high CR rate of approximately 95% (28,29,30). When used 
in patients with de novo Ph+ ALL it improves complete response (hematologic, 
cytogenetic and molecular), prolongs time to relapse, improves transplant eligibility 
and leukemia free survival. 
 
There are theoretical advantges in the potential initial use of second generation TKI’s 
like increased potency (dasatinib, nilotinib, bosutinib and ponatinib), broader 
spectrum of activity in kinase inhibition (dasatinib and ponatinib) and better 
penetration in the CNS potentially reducing local relapse (dasatinib). 
 
Results from studies of dasatinib are beginning to be available (24). In an Italian study, 
100% of patients with de novo Ph+ ALL who were treated with dasatinib in 
combination with steroids (but without chemotherapy) achieved CR within 1 month 
of starting the treatment (31).  
 
Ponatinib has been reported to be effective in CML patients whith the T315I mutation 
which confers resistance to imatinib, so it can be considered in ALL if there is 
evidence of such mutation. 
 
No studies have examined the optimal duration of treatment with TKIs during 
induction, consolidation and maintenance. Comparative clinical data and literature is 
still insufficient regarding comparisons between TKIs. 
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3.2. Philadelphia chromosome-like (Ph-like) ALL 
 
Ph-like ALL, a recently described entity, is characterised by a similar gene expression 
profile to Ph+ ALL; alterations in lymphoid transcription factor genes; and a bad 
prognosis (32,33). Patients with Ph-like ALL do not have the BCR-ABL1 fusion gene, 
instead, a diverse range of genetic alterations that deregulate cytokine receptor and 
tyrosine kinase signalling has been observed.  
 
Ph-like ALL increases in frequency from 10% among children with standard risk 
ALL to 27% among young adults and is associated with a poorer outcome. 
 
The frequency and spectrum of genetic alterations in Ph-like ALL and the response to 
tyrosine kinase inhibitors is yet undefined.  
 
About 90% of patients with Ph-like ALL have kinase activating alterations (34). There 
are distinct subgroups of kinase and cytokine receptor genes alterations; The 
frequency of these subgroups also varies with age: 
- Rearrangements involving ABL-class tyrosine kinase genes (ABL1, ABL2, 
CSF1R, PDGFRB) predicted to respond to ABL1 inhibitors (12,6% of cases); 
- Rearrangements involving CRLF2 (49,7% of cases) predicted to respond to 
JAK2 inhibitors in many cases; 
- Rearrangements of EPOR (3,9% of cases) or JAK2 (7,4% of cases) predicted 
to respond to JAK 2 inhibitors; 
- Genetic alterations of IL7R, FLT3, SH2B3, JAK1, JAK3, TYK2, IL2RB  
- RAS pathway mutations (4,3% of cases) 
- Uncommon fusions involving NTRK3 or DGKH (0,9% of cases) 
 
The expression of fusion products involving ABL1, ABL2, CSF1R and PDGFRB 
resulted in cytokine-independent proliferation and activation of phosphorylated 
STAT5 (34). 
 
Cell lineages and human leukemic cells that expressed fusions with ABL1, ABL2, 
CSF1R and PDGFRB were sensitive in vitro to dasatinib (ABL inhibitor), the 
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rearrangements with EPOR and JAK2 were sensitive to ruxolitinib (JAK inhibitor) 
and the fusion ETV6-NTRK3 to crizotinib (ALK inhibitor) (35,36,37). 
 
Direct targeting of RAS is challenging but targeting of signalling pathways 
downstream of this protein may be considered. 
 
The frequency of Ph-like ALL is higher than 25% among young adults with ALL. 
Once BCR-ABL1 + ALL represents more than 20% of pre B ALL cases in this age 
group, about half of young adults with pre B ALL are candidates for tyrosine kinase 
inhibitory therapy. 
 
Opportunities to match genomic discoveries with the management of ALL are 
becoming available, from initial diagnosis and risk stratification to the delivery of 
targeted therapy. Sequencing will be increasingly used for molecular diagnosis 
because many genetic alterations are undetectable using our current tests – Ph-like 
ALL is a notable example (34). 
 
Clinical trials with tyrosine kinase inhibitors in this population are warranted. 
 
4. Immunotherapy in ALL 
 
4.1. Rational of Immunotherapy in ALL 
 
Malignant cells are continuously eliminated by apoptosis and by the immune system 
yet cancers escape these mechanisms. So that immune mediated clearance of 
leukemic cells becomes possible, immune tolerance must be overcome. This is the 
basis for the graft-versus-leukemia effect that contributes in part for the efficacy of 
allogenic hematopoietic stem cell transplant and is also the rational for the donor 
lymphocyte infusion in leukemia (38). Although donor lymphocyte infusion has 
revealed to be less effective in ALL, graft versus leukaemia effect is recognized.  
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A recent clinical trial from the Children Oncology Group demonstrated that the 
relapse rate in children who developed graft-versus-host disease after allogenic 
hematopoietic stem cell transplant was significantly lower than in children who did 
not develop it (39). However the graft versus leukaemia effect carries a significant risk 
of graft versus host disease. 
 
4.2. Therapy with monoclonal antibodies 
 
Leukemic blasts in ALL express several surface antigens susceptible of being targeted 
by directed therapies including CD19, CD20, CD22 and CD52. Monoclonal 
antibodies are able to target these antigens selectively, minimizing off-target toxicity. 
Monoclonal antibodies exert their function through various mechanisms that include 
direct cytotoxicity, complement-dependent cytotoxicity and apoptosis induction. If 
the target internalizes upon binding with the antibody then potent cytotoxines can be 
conjugated producing an additional mechanism (1). 
 
When added to first-line chemotherapy, rituximab (anti-CD20), increased Burkitt 
leukemia cure rates in adults from 40% to 80% and pre B-ALL cure rates from 35 to 
50% (8). Inotuzumab ozogamicin (anti-CD22 linked to calicheamicin) originated 
complete remission rates of 55% and median survival of 6 to 7 months when given to 
patients with relapsed/ refractory ALL (1,40,41). Blinatumomab – a biallelic monoclonal 
antibody to T cells CD3-CD19 has also resulted in global responses of 40 to 50% and 
a median survival of 6,5 months in a similar population (1,42). Other promising 
monoclonal antibodies against CD20 (ofatumumab and obinutuzumab) or CD19 and 
linked to different cytotoxins or immunotoxins are in development. 
4.2.1. CD20 directed therapy 
 
CD20 surface antigen is observed in 30 to 50% of B cell precursor lymphoblasts (1,43). 
Rituximab is a chimeric monoclonal antibody originally developed and approved for 
the treatment of non-Hodgkin lymphoma. Several studies have reported that the 
addition of rituximab to chemotherapy improved cure rates of Burkitt ALL (8). Two 
studies have shown the same for pre-B ALL. Rituximab is preconized in addition to 
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Hyper-CVAD in patients diagnosed with Ph – ALL, CD20+. The majority of 
protocols restricts its use to patients whose blasts express CD20 in more than 20%. 
There is an on-going study to determine the safety of intraventricular rituximab in 
patients with relapsed ALL in the CNS (44). This antibody is generally well tolerated 
and the majority of its adverse effects are related to the infusion. 
 
Ofatumumab is a second-generation anti-CD20 monoclonal antibody that binds to a 
different place than rituximab being more potent (1,45). In chronic lymphocytic 
leukemia this antibody has demonstrated significant activity after previous exposure 
to rituximab (1,46). In a phase 2 study in pre-B ALL, the combination of HCVAD with 
ofatumumab was very effective. 25 patients with pre-B ALL de novo were treated. 
CR rates and minimal residual disease rates were both negative in 96%. With a 
median follow-up of 14 months, disease free survival and global survival rate were 94 
and 92%, respectively (47). 
 
Obinutuzumab is a new anti-CD20 antibody that is superior to the latter in the 
induction of cellular death. Investigation in CD20+ ALL patients is warranted after 
the promising results that it showed in CLL in combination with clorambucil (1,48). 
4.2.2. CD19 directed therapy 
 
CD19 is expressed in B cells since their early stages of differentiation. After the 
antibody binds to this antigen, it internalizes becoming a potential target of 
immunoconjugated therapies (1,49). 
 
Blinatumomab is a bispecific antibody that also binds to T cells. It contains both the 
variable domains of an anti-CD19 and anti-CD3 antibodies linked by a non-
immunogenic linker. When it links to CD19, an activation of cytotoxic T cells 
inducing cellular death by the perforin system occurs(1,50). 
 
The continuous administration during several weeks instead of an intermittent one, 2 
to 3 times per week, increased significantly its activity while minimizing adverse 
effects (50). 
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The activity of this antibody was already studied in minimal residual disease and in 
relapsing/ refractory disease (52,53). 
 
The first study of blinatumomab using continuous infusion evaluated its potential in 
the eradication of minimal residual disease (1,51). Minimal residual disease in ALL is 
associated almost always with systemic relapse and bad prognosis. A dose of 
15ug/m2 was administrated daily as a continuous infusion during 28 days, every 6 
weeks. After completing one cycle, patients could receive more 3 cycles of additional 
consolidation or proceed to allogenic stem cell transplant if a compatible donor was 
available. Minimal residual disease conversion was observed after completing the first 
cycle in 16 of 20 evaluated patients (80%). In a longer follow up (median of 33 
months) 12 of the 20 patients continued in complete remission, relapse-free survival 
at 3 years was 60%. 9 patients proceeded to transplant but, surprisingly, with 
outcomes similar to the non-transplant group.  The majority of relapses occurred in 
the first 7 months after therapy. 
 
A few hours after the beginning of the infusion, a rapid redistribution of T cells was 
observed – after a rapid reduction, T cells recovered immediately to pre-treatment 
levels and expanded above the basal level during the rest of the course of the first 
infusion. This pattern was observed in 8 of 17 patients evaluated. Although the 
increase was due to the subpopulations CD4+ and CD8+, memory T cells was the 
predominant subpopulation. 
 
Blinatumomab was subsequently studied in patients with relapsed ALL (52,53). The 
results of this trial were recently updated. 3 dose schedules were explored using the 
latter scheme. The global response rate with two cycles of therapy was 69%. The 
median survival was 9,8 months. The final dosage selected for future trials was 
5ug/m2 during the first week followed by 15ug/m2 for the next 3 weeks. 
 
The adverse effects more commonly observed after administration include fever, 
chills and hipogammaglobulinemia. Tremor, headaches and mental status alterations 
were also reported. Fever, chills and constitutional symptoms are provoked by a 
cytokine releasing syndrome that occurs early after therapy and that is reduced with 
corticosteroids. This syndrome will be discussed later in this article. 
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There are currently other therapies with immunoconjugates directed at CD19 being 
developed. SAR3419 is an antibody directed at CD19 conjugated with a maitansinoid 
compound – an anti-mitotic agent that binds to tubulin (similar to vincristine). These 
compounds are much more powerful than vinka alkaloids but their toxicity profile has 
led to their abandonment in conventional chemotherapy. This immunoconjugate has 
shown efficacy in pre-clinical models. As a limiting factor there is turve vision due to 
cornea epithelial alterations (1,54,55). SGN-DC19A is another immunoconjugate with 
the antimicrotubule agent Auristatin F (MMAF). Upon binding to CD19, the 
compound internalizes delivering MMAF that binds to tubulin inducing G2/M arrest 
and apoptosis (56). Phase 1 studies are being performed to determine dosage. The 
adverse effects consist in nausea, fever, chills and headache. 
4.2.3. CD22 directed therapy 
 
CD22 is expressed in the lymphoblast in more than 90% of ALL patients (43). After 
binding to an antibody, the complex is rapidly internalized which makes it an 
attractive target for antibodies conjugated with cytotoxic agents (57). 
 
Epratuzumab is a non conjugated antibody that has already been studied in pediatric 
relapsed ALL; with this antibody used alone, the majority of patients had stable 
disease and only one of 15 treated patients had a partial response.  Despite showing 
modest activity the best therapies directed at CD22 are probably those that use 
immunoconjugates (58). 
 
Inotuzumab ozogamicin is the more developed anti-CD22 immunoconjugate. The 
antibody is linked to calicheamicin – a cytotoxin that induces gaps in the double 
strand of DNA (59). Reversible thrombocytopenia is a frequent adverse reaction (60). 
Hepatic function abnormalities were also observed as well as the development of 
veno-oclusive disease in patients that followed to transplant. In relapsed/ refractory 
ALL this immunoconjugate has shown very promising results which motivated its 
further study in combination with low intensity HCVAD in older patients (ages 
between 60 and 79). All the patients with cytogenetic anomalies achieved a complete 
cytogenetic response and all patients that had a response also had negative status for 
 14 
 
minimal residual disease. The survival at one year was superior to previous results 
obtained with HCVAD+rituximab in a similar population (61). 
 
Moxetumomab pasudotox is an immunotoxin constituted by a variable fragment 
derived from an anti-CD22 monoclonal antibody fused to pseudomonas aeruginosa 
exotoxin A. In a phase 1 study, 21 children and adolescents with relapsed/ refractory 
ALL were treated with this immunotoxin. From the 17 evaluable patients, 24% 
achieved CR, 6% obtained a partial response and 47% achieved hematologic 
improvements for a global activity rate of 70% (62). Trials with this antibody 
administered in a higher frequency and dosage are on-going. 
4.2.4. CD52 directed therapy 
 
For the patients with T phenotype ALL, therapeutic options with antibodies are very 
limited. Alentuzumab is a humanized monoclonal antibody against CD52. This 
antigen is expressed in 36 to 66% of leukemias, including B ALL; T ALL and AML. 
However the outcomes obtained with this antibody were not promising adding to its 
profound adverse effects (63). 
4.3. Therapy with CAR-T cells 
 
Therapy with CAR (chimeric antigen receptor) - T cells is an immunotherapy that has 
emerged as a powerful weapon and has been showing promising responses. In this 
therapy, T cells are removed from the patient, reprogrammed in laboratory to identify 
and eliminate malignant cells through tumor-specific antigen recognition, and 
reintroduced (39). 
 
The T cell begins to show in its membrane a synthetic chimeric receptor for a specific 
antigen becoming reactive against all cells that express it. Contrarily to T cell receptor 
(TCR), CAR can link to structures in an MHC independent fashion (64,65). 
 
The receptors are called chimeric because they are made of parts derived from 
different sources. They are constituted by an ectodomain that contains the signal 
peptide, the antigen-recognizing region and a spacer; a trans membrane domain; and 
an endodomain. 
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The concept was first described 25 years ago. The first design made the linkage of a 
single chain variable fragment (scFv) derived from an antibody, to the intracellular 
signalling domain CD3 ζ of TCR, through a trans membrane domain and a spacer. 
This fundamental design has led to the designation of the first generation CARs (65). 
 
The recruited intracellular signalling domain CD3ζ activates and induces T cell 
proliferation, however it can lead to anergy. Once it was necessary to optimize T cell 
proliferation and persistence, both in vitro and in vivo, modifications were made that 
led to the second and third generation CARS. Second generation CARs incorporate an 
additional domain – either CD28 or 4-1BB to provide a co-stimulatory signal. Third 
generation CARS incorporate two additional domains – a combination among CD27, 
CD28, 4-1BB, ICOS or OX40. It is not known which is the best co-stimulatory 
combination – similar anti-tumour effects were observed in vitro with second 
generation CARS with CD28 and with 4-1BB (67), however, pre-clinical studies in 
vivo suggest that the latter are associated with greater proliferation and persistence of 
T cells (68). 
 
The spacer and trans membrane domain are probably the least studied subjects and 
they can have important contributions in the interaction with the antigen, in the 
formation of the immunologic synapse and in the association of CARs to other 
proteins necessary to transduce a robust signal activation (39). 
 
There are currently available several technologies of genetic transference that can be 
used to modify T cells, each of which, with its advantages and disadvantages in their 
price, safety and level of expression – since viral vectors as y-retrovirus and lentivirus 
that result in a permanent genome modification to RNA based methods that only lead 
to a transitory gene expression. Viral vectors have the advantage of long lasting 
expression, on the other hand they lead to permanent on-target toxicity and risk of 
transformation if the genic insertion results in an oncogene deregulation, the latter is 
only a theoretical risk  (39,65). 
 
An important variable that influences the proliferative capacity and T cell persistence 
is the ex vivo culture system used in the production of CAR-T cells (66). Several 
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systems were developed that use antibodies and/or artificial APC with cytokine 
support to stimulate the T cells. Their differences influence the final composition in 
effector, naive and memory T cells. While the first are able to mediate a potent 
cytotoxicity they have a reduced proliferative capacity because they are terminal 
differentiated.  
 
Relatively to the ideal target of CAR-T cells in ALL this would be tumour-specific, 
expressed ubiquitously in all lymphoblasts and not expressed in normal cells. This 
antigen is difficult to find but there are viable alternatives (39). The surface protein 
CD19 is expressed during the development of B cell lineage and is expressed in 
almost all of B cell cancers including ALL, CLL and many non-Hodgkin lymphomas. 
Its level of expression as well as its specificity for B cell has made it an attractive 
target for CAR-T cells. Other B cell specific molecules as CD22 are also promising 
and are under current investigation (39). 
 
The identification of targets to phenotype T ALL is a particular challenge once 
lymphoblasts express the same antigen as normal T cells. While B cell aplasia is 
treatable and tolerable, T cell aplasia is not. Although some specific subgroups of T 
cell leukemias express aberrantly abnormal fusion proteins there is no universal 
target. 
 
At present, all publications about CAR T cells usage in hematologic malignancies are 
in B cell cancers having as a target CD19 or CD20. The other one refers to acute 
myeloid leukaemia having as a target the Lewis-Y antigen (65). Each group has 
designed different protocols and they vary in the design of CARS, its expression in T 
cells, cellular culture conditions, lymphodepletion strategy used and timing of the 
infusion of CAR-T cells in relation to standard therapy (65). 
 
It is not surprising that CAR-T cells directed at hematologic malignancies have been 
the first to be tested, given the extent of knowledge about surface antigens expressed 
in these cancers, the relative simplicity in obtaining tumour samples and the natural 
preference of T cells in homing to hematologic organs as the blood, bone marrow and 
lymphoid nodes. 
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The clinical trials in CLL and ALL demonstrated high activity and very good clinical 
responses. Initial reports included a low number of patients but were notable in the 
remissions induced in patients with relapsed/ refractory CLL and in patients with 
highly refractory ALL that were considered incurable (65). 
 
CR rates as high as 90% were observed in children and adults with relapsed/ 
refractory ALL treated with CAR-T cells directed against CD19 (39). 
 
The first reports were expanded to determine the complete remission rate and at 
present 3 groups using different models of CARs have published their results. The 
efficacy is even better than expected with CR rates of about 70 to 90%. 
  
- A CR rate of 90% was obtained in a cohort of 30 patients (children and adults) 
with relapsed/ refractory ALL treated in the Children’s Hospital of 
Philadelphia (CHOP) and University of Pennsylvania (70). 
- A CR rate of 88% was obtained in a cohort of 16 adult patients with relapsed 
ALL treated in the Memorial Sloan-Kettering Cancer Center (MSKCC) (69). 
- A CR rate of 70% was obtained in a cohort of 20 children and young adults 
with ALL in an intent-to-treat analysis of the National Cancer Institute (71). 
 
The three studies included patients with previous history of allogenic hematopoietic 
stem cell transplant not having had graft versus host disease. The initial response is 
comparable in all studies, however CARs persistence and long term outcomes can 
vary and distinguish CAR designs. 
 
Distinct design of CARs in various studies produced similar results. Durable 
remissions were observed in patients not subjected to additional therapy. Data has 
suggested that CAR-T cells design is associated with cell persistence and remission 
duration, however more studies are necessary with a more regular follow-up. 
 
The most common and potentially dangerous adverse reaction associated with this 
therapy is cytokine releasing syndrome. There is a correlation between the 
development of this syndrome and the response to therapy. Patients who do not 
develop it seem to have less benefit (39). 
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Similarly to other T cell activating therapies, including therapy with blinatumomab, 
the severity of this syndrome is related to the tumour burden at the time of the 
infusion.  
 
Cytokine releasing syndrome is a systemic inflammatory process derived from the 
exponential proliferation of T cells with resultant marked elevation in cytokine levels. 
Symptoms vary from mild flu-like symptoms to shock and multiorgan insufficiency. 
The cytokine elevation profile resembles that seen in macrophage activation 
syndrome/ hemophagocytic lymphohistiocitosis with marked elevations of sIL2Ra, 
IL-6, IL-10 and IFN-y. Patients develop similar clinical and laboratory features 
including marked hyperferritinemia, hepato/splenomegaly and hipofibrinogenimia (39). 
 
A better knowledge of this syndrome is needed to predict which cytokines are 
necessary for therapeutic efficacy, and which are not and that can become potential 
candidates for pharmacologic targeting. 
 
The high levels of IFN-y liberated by cytotoxic T cells may be important to 
therapeutic efficacy. The same is true for the high levels of sIL2-Ra. IL-10 is a 
negative regulator of macrophage function so that its inhibition could actually worsen 
the syndrome. IL-6 is a pro-inflammatory cytokine that may be a good target for 
inhibition when treating this syndrome (39). 
 
IL-6 antagonists have already been used in cytokine releasing syndrome. Tocilizumab 
was given to ten patients and a frank improvement was observed without alterations 
in therapy efficacy. The majority of patients had a rapid improvement and complete 
resolution of the syndrome. This agent is well tolerated with rare toxicities that 
include hepatic inflammation and cytopenias, but they were reported only in chronic 
use. There are other IL-6 antagonists like siltuximab, sarilumab and olokizumab (69). 
 
Corticosteroids are used frequently in this syndrome when it is triggered by 
blinatumomab, however there are concerns about its potential neutralizing effects in 
CAR-T cells function when administered in this scenario. 
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Tumour burden in the moment of the infusion is the best predictor of severity of this 
syndrome. CRP was proposed as a marker of severity once its elevation is 
proportional to the severity of the syndrome, however its role as predictive biomarker 
is currently under investigation. In future, cytokine levels monitoring might be used to 
determine the need for therapy with cytokine blocking agents like tocilizumab (39). 
 
After T cell activating therapies, severe neurologic toxicities can occur. Global 
encephalopathy is the most common adverse reaction however seizures are also 
possible. The encephalopathy is generally mild and self-limited. CT scans and MRI as 
well as lumbar puncture have not revealed a specific etiology for this syndrome. 
CAR-T cells have been found in the cerebrospinal fluid in the majority of patients 
even those who do not develop neurologic toxicity. Tocilizumab administration does 
not appear to decrease the incidence of these adverse reactions (39,69) 
 
Chronic B cell aplasia and resultant hypogammaglobulinemia is an on-target adverse 
reaction that is expected in this therapy as it eliminates normal mature B lymphocytes 
as well as pre-B cells. As CAR-T cells persistence increases, the greater is this 
toxicity – in fact it functions as a good pharmacodynamic biomarker. Despite the fact 
that iv administration of immunoglobulin decreases most infectious complications, a 
longer follow-up is necessary to evaluate late consequences of B cell aplasia (39). 
5. Advances in the treatment of T-ALL  
 
T-ALL accounts for 15% of childhood cases and 25% of adult cases of ALL. Current 
chemotherapy regimens cure about 85% of children with T-ALL but only 50% of 
adults. T-ALL treatment evolved since the use of standard non-Hodgkin lymphoma 
regimens to standard ALL regimens. The application of pediatric intensive 
chemotherapy regimens to AYA has significantly improved prognosis, as previously 
mentioned (72). 
 
An important therapeutic agent in T-ALL treatment is nelarabine. This agent has 
already a well established role in relapsed/ refractory ALL achieving CR rates of 
31%, global response rates of 41% and 1-year survival of 28%. It has been combined 
with first line chemotherapy in both adult and pediatric patients. In adults it has been 
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combined with hyper-CVAD as initial treatment. Neurotoxicity is the most important 
side effect (72). 
 
The development of new agents for T-ALL therapy did not follow that for B-ALL. 
Molecular studies are improving our knowledge on T-ALL pathogeny and the 
discovery of NOTCH1 and FBXW7 activating mutations was very relevant. 
 
Activating mutations in the gene encoding NOTCH1 cause more than half of T-ALL 
cases. NOTCH1 is a transmembrane cell surface receptor that regulates normal T cell 
development. Upon interaction of the extracellular domain with its respective ligands, 
an intramembrane presenilin–y-secretase protease complex is activated that liberates 
the intracellular domain of NOTCH1 - ICN1 -  from the lipid bilayer. Then, ICN1 
translocates to the nucleus, associates with the transcription factor CSL6 and activates 
the transcription of a set of target genes including the proliferation promoting 
oncogene MYC.  
 
Once NOTCH1 receptor is activated by y-secretase complex, y-secretase inhibitors 
(GSIs) are promising for the treatment of patients with NOTCH1 mutations. There are 
several GSIs currently under development, one of them, MK-0752 has shown 
significant gastrointestinal toxicity obtaining only transitory responses, however other 
inhibitors are being developed and showing moderate efficacy (73). 
 
Combining these inhibitors with glucocorticoids can eventually provide a more 
effective and safer approach. Studies in cell lines and patient samples demonstrated 
that combining GSIs and glucocorticoids can induce apoptotic cell death in 
glucocorticoid resistant T-ALL cells while simultaneously decreasing the 
gastrointestinal toxicity seen in experimental mice and rats. 
 
The effects of long-term inhibition of y-secretase are unknown; this enzyme targets 
more than 30 physiologically important transmembrane proteins, including the 
amyloid precursor protein involved in Alzheimer’s disease. There are at least six 
different y-secretase complexes in humans and subtype specific inhibitors might be 
developed that have less side effects. 
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Despite the promise of this approach for NOTCH1-activated T-ALL, not all people 
with this condition would be expected to respond.  
 
Eight percent of T-ALL samples have mutations or even homozygous deletion of 
FBXW7, a gene that encodes a ubiquitin ligase that is responsible for NOTCH1 ICN1 
turnover. These cells are resistant to treatment with GSIs. 
 
Some cases of T-ALL are suitable to therapies with TKIs. The NUP214-ABL1 
rearrangement is present in 5% of T ALL and may benefit of tyrosine kinase 
inhibitors directed at ABL1. For T-ALL with JAK3 or IL7-R activating mutations 
there is also the possibility of using TKIs directed to JAK-STAT like tofacitinib (74). 
 
Other targeted molecules are also being studied for T-ALL but one that shows 
efficacy for all cases of this condition is not yet in the horizon. 
6. Conclusion 
 
The advances in standard chemotherapy regimens have reached a plateau, which is 
motivating the search for other solutions for ALL patients. New pharmacological 
agents have in common the fact of being directed to specific targets and they can 
involve the immune system in a more direct or indirect manner.  
 
As these agents are being incorporated in therapeutic regimens several important 
questions are arising: Can multiple directed agents be incorporated in a single 
regimen? Should they be used simultaneously or sequentially and what is the optimal 
sequence? What is the optimal standard chemotherapy dose when using these agents? 
Can we anticipate the use of conventional chemotherapy for refractory/ relapsed 
disease in the future? Can we expect much better results for adult patients treated with 
directed therapies? 
 
The advances in the general support of patients with hematologic cancers like in the 
treatment of infections, control of cytopenias, therapeutic toxicity management, 
psychosocial support and the advances in transplant methods are also very important 
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to consider. They have already contributed a lot for these patient’s prognosis and it’s 
necessary to continue investing in this topic. 
 
Waves of new pharmacological agents are passing with many molecules continuously 
appearing and disappearing from clinical trials. It is an important challenge enrolling 
patients in the best trial for them. 
 
The price of these new medications is, in general, still very high and it is necessary to 
study its implementation in our national health care systems and also to discriminate 
which patients have the best benefit. 
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